Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Formulations of Terlipressin

a technology of terlipressin and terlipressin, which is applied in the direction of infusion syringes, peptide/protein ingredients, inorganic non-active ingredients, etc., and can solve the problem of side effects in up to 40% of patients

Inactive Publication Date: 2022-06-30
BIOVIE INC
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes an aqueous composition that contains terlipressin acetate or a pharmaceutically acceptable salt thereof. The composition has a specific pH range and is stable at room temperature for at least 24 months. The composition is also stable at temperatures between 25°C and 50°C for at least 24 hours. The composition can be stored at 40°C and 75% relative humidity for up to 12 weeks. The composition can be administered through a pre-filled syringe or through a continuous infusion device. The patent also provides a kit for preparing and administering the composition. The technical effects of the patent are a stable and safe aqueous composition of terlipressin acetate that can be stored for a long time and administered through various means.

Problems solved by technology

Additionally, terlipressin can cause side effects in up to 40% of patients.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Formulations of Terlipressin
  • Formulations of Terlipressin
  • Formulations of Terlipressin

Examples

Experimental program
Comparison scheme
Effect test

example 1

Acid Formulations

[0091]Terlipressin acetate formulations containing aspartic acid (with and without nitrogen) at a pH of 4.5 are prepared.

[0092]With Nitrogen Protection: Perform all procedures using N2 protection. Sparge water for injection (WFI) prior to addition of materials. Overlay N2 during mix operations, discontinuing only to add solid materials. Keep solution at 20-25 ° C.

[0093]Add WFI to formulation vessel, equivalent to 80% of the final QS volume.

[0094]Add aspartic acid to WFI; rinse aspartic acid weighing vessel with WFI (rinse volume < / =to 3% of final volume). Mix to dissolve

[0095]Adjust pH to 4.0 with 0.1 N NaOH solution.

[0096]Add terlipressin acetate with WFI rinses (rinse volume < / =5% of QS volume). Mix to dissolve.

[0097]Adjust pH to 4.5 with either 0.1 N NaOH or 0.1 N acetic acid solution (expect the pH to be 4.6 after addition of terlipressin acetate to pH 4.0 solution).

[0098]Bring to final volume with low O2 WFI. Readjust pH if required.

[0099]Without Nitrogen Prote...

example 2

id Formulations

[0107]Terlipressin acetate formulations containing acetic acid (with and without nitrogen) at a pH of 4.5 are prepared.

[0108]With Nitrogen Protection: Perform all procedures using N2 protection. Sparge WFI prior to addition of materials. Overlay N2 during mix operations, discontinuing only to add solid materials. Keep solution at 20-25° C.

[0109]Add WFI to formulation vessel, equivalent to 80% of the final QS volume.

[0110]Add acetic acid to WFI; rinse ascetic acid weighing vessel with WFI (rinse volume < / = to 3% of final volume). Mix to dissolve

[0111]Adjust pH to 4.0 with 0.1 N NaOH solution.

[0112]Add terlipressin acetate with WFI rinses (rinse volume < / =5% of QS volume). Mix to dissolve.

[0113]Adjust pH to 4.5 with either 0.1 N NaOH or 0.1 N acetic acid solution (expect the pH to be 4.6 after addition of terlipressin acetate to pH 4.0 solution).

[0114]Bring to final volume with low O2 WFI. Readjust pH if required.

[0115]Without Nitrogen Protection: Keep solution at 20-25...

example 3

of Terlipressin Formulations

[0123]The impact of aspartic acid formulations with and without nitrogen at pH 4.5 and acetic acid formulations with and without nitrogen at pH 4.5 were assessed at 2° C.-8° C., 25° C. and 40° C. at 3 months and 4 months. The aspartic acid and acetic acid formulations were prepared by methods similar to those described in Examples 1 and 2. The results shown in Tables 6-9 below are shown in terms of % label strength (LS) for the active ingredient (terlipressin acetate), as well as the % change as compared to the day 0 (initial) time point. Table 10 shows a comparison of the %LS data presented in Tables 6-9. Percent label strength was calculated using the following formula: (mg / mL found) / (1.0 mg / mL label strength)×100%.

TABLE 6Aspartic Acid Formulation at pH 4.5 Stability2° C-8° C.25° C.40° C.Time%%%%%%(months)LSchangeLSchangeLSchange096.95—96.95—96.95—396.53−0.4295.87−1.0894.00−2.95498.341.3997.380.4394.30−2.65

TABLE 7Aspartic Acid Formulation with Nitrogen ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Temperatureaaaaaaaaaa
Temperatureaaaaaaaaaa
Temperatureaaaaaaaaaa
Login to View More

Abstract

The disclosure provides pharmaceutical compositions comprising terlipressin having increased concentration with long term storage stability.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of U.S. patent application Ser. No. 17 / 611,478, filed Nov. 15, 2021, which is a U.S. national phase under 35 U.S.C. § 371 of International Application No. PCT / US2020 / 034269, filed May 22, 2020, which claims priority to U.S. Provisional Patent Application Serial Number 62 / 851,366, filed May 22, 2019, the contents of each of which are hereby incorporated by reference in their entirety.BACKGROUNDField[0002]The disclosure is directed to stable pharmaceutical compositions of terlipressin having increased concentrations at room or ambient temperature or under refrigeration.Technical Background[0003]Terlipressin is a synthetic vasopressin that is approved in many countries outside of the United States to treat the life-threatening complications of cirrhosis, including hepatorenal syndrome (HRS) and esophageal bleeding (EVB). Its use is limited to the hospital setting due to its short half-life (Nilsson, et al.,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/22A61M5/00A61M5/178
CPCA61K38/2278A61M5/178A61M5/002A61K9/08A61K9/0019A61K47/12A61K38/095A61K47/183A61K47/26A61K47/02A61K47/20A61K38/12A61M5/14248
Inventor MARKHAM, PENELOPEADAMS, JONATHANSMITH, DENISEBACARDIT CABADO, JORGE
Owner BIOVIE INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com